Al-Wakeel Yasir B.

SEC source: 0000905148-26-003049 · form4.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,579

Underlying: Common Stock · 49,579 shares

Expires 2036-06-16

F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0000905148-26-003049 · form4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,998

F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0000905148-25-002228 · form4.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,790

Underlying: Common Stock · 50,790 shares

Expires 2035-06-17

F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0000905148-25-002228 · form4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,577

F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-016710 · form4-06132024_090651.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,701

Underlying: Common Stock · 40,701 shares

Expires 2034-06-10

F2 · derivative.exercise_date: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-016710 · form4-06132024_090651.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,367

F1 · shares: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · shares: This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 11, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001209191-23-041786 · doc4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 346,102

F1 · shares: Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $1.7523, and the range of prices were between $1.65 and $1.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-039486 · doc4.xml · derivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-06-21

F1 · derivative.exercise_date: This annual option grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this option vest on June 22, 2024, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001209191-23-020291 · doc4.xml · derivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-03-19

F1 · derivative.exercise_date: This grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. 23,333 of the shares underlying this option vested on March 20, 2023 and the remaining 16,667 shares will vest in 15 equal monthly installments thereafter, beginning on April 14, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001209191-23-013015 · doc4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 355,719

F1 · shares: Represents shares sold to satisfy estimated tax withholding obligations upon the settlement of restricted stock units.

SEC source: 0001209191-23-010574 · doc4.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,367

Underlying: Common Stock · 208,367 shares

Expires 2033-02-14

F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-23-010574 · doc4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 364,745

F1 · balance_after: Includes an aggregate of 8,993 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on the following dates: 1,478 shares on June 30, 2021, 1,039 shares on December 31, 2021 and 6,476 shares on December 30, 2022.

SEC source: 0001209191-22-043290 · doc4.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-07-24

F1 · derivative.exercise_date: 50% of the shares subject to the stock option shall vest and become exercisable on June 30, 2023 and the remaining shares shall vest and become exercisable on December 31, 2023.

SEC source: 0001209191-22-043290 · doc4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 216,841

SEC source: 0001209191-22-041614 · doc4.xml · derivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,900

Underlying: Common Stock · 26,900 shares

Expires 2032-06-28

F1 · derivative.exercise_date: This annual option grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this option vest on June 29, 2023, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001209191-22-010899 · doc4.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-02-14

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-22-010899 · doc4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,241

SEC source: 0001209191-21-050925 · doc4.xml · derivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-08-09

F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0001209191-20-062941 · doc4.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,633

Underlying: Common Stock · 108,633 shares

Expires 2030-12-08

F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant.

SEC source: 0001209191-20-062941 · doc4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,641

SEC source: 0001209191-20-055034 · doc4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,219

SEC source: 0001694187-20-000063 · wf-form4_158881354959855.xml · derivative · entry 4

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

SEC source: 0001694187-20-000063 · wf-form4_158881354959855.xml · derivative · entry 3

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 61,031 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

SEC source: 0001694187-20-000063 · wf-form4_158881354959855.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 192,759 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the "Cash Merger Consideration").

SEC source: 0001694187-20-000063 · wf-form4_158881354959855.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 154,584 restricted stock units (each, an "RSU") held by the Reporting Person.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE ("BioNTech"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of May 6, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 0.063 (the "Exchange Ratio") of American Depositary Shares of BioNTech ("BioNTech ADS") plus the right, if any, to receive cash in lieu of fractional shares of BioNTech ADSs into which such Shares would have been converted. This number includes 154,584 restricted stock units (each, an "RSU") held by the Reporting Person.

SEC source: 0001694187-20-000028 · wf-form4_158319232407113.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,965

F1 · shares: These shares represent shares withheld to satisfy tax obligations arising from the vesting of restricted stock units awarded to the reporting person on February 27, 2019 and do not represent a discretionary trade by the reporting person. The number of shares to be withheld was determinable on February 29, 2020.

SEC source: 0001694187-20-000014 · wf-form4_158284568348788.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 201,856

F1 · shares: These shares represent shares withheld to satisfy tax obligations arising from the vesting of restricted stock units awarded to the reporting person on November 25, 2019 and do not represent a discretionary trade by the reporting person. The number of shares to be withheld was determinable on February 25, 2020.

SEC source: 0001694187-20-000005 · wf-form4_157895282153345.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,241

F1 · shares: Dr. Al-Wakeel was awarded 65,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on January 31, 2021 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

SEC source: 0001694187-19-000076 · wf-form4_157472066645597.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 142,241

F1 · shares: Dr. Al-Wakeel was awarded 75,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest quarterly over one year, subject to the Reporting Person's continued service, with the first tranche vesting on February 25, 2020. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

SEC source: 0001694187-19-000010 · wf-form4_155148224874668.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2029-02-26

F2 · derivative.exercise_date: This option shall vest and become exercisable in equal monthly installments over four years commencing on February 27, 2019.

SEC source: 0001694187-19-000010 · wf-form4_155148224874668.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,241

F1 · shares: Dr. Al-Wakeel was awarded 50,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. The Restricted Stock Units shall vest annually over three years, with one-third vesting on the last day of February 2020 and the balance vesting in two equal annual installments thereafter, subject to the Reporting Person's continued service. The Restricted Stock Units may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

SEC source: 0001104659-18-045783 · a4.xml · derivative · entry 2

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,759

Underlying: Common Stock · 17,241 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% shares vested on July 5, 2018, with the remainder vesting over 12 equal quarterly installments thereafter.

F1 · derivative.expiration_date: 25% shares vested on July 5, 2018, with the remainder vesting over 12 equal quarterly installments thereafter.

SEC source: 0001104659-18-045783 · a4.xml · nonDerivative · entry 1

Al-Wakeel Yasir B. · CIK 0001650691 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,241

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.